Lyell Immunopharma Inc (LYEL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$12.88-4.80%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Stabilize and grow revenue beyond FY26: FY27 rev +6.9% vs >-60% target.
Lyell is developing new T-cell therapies for solid tumors. It aims to maintain cash sufficiency into Q3 2027. Recent earnings beats show some operational progress. The company has a new CFO with relevant experience.
Lyell is loss-making with negative free cash flow. Analysts expect revenue to shrink about 60% next year. The stock has sold off sharply and faces elevated risk. Cash sufficiency beyond Q3 2027 is uncertain.
The price is about 35% below our fair value near $24. Analysts expect about 60% revenue decline. Our fair value is 46% below the Street median, reflecting skepticism on recovery.
Breaks if: Cash sufficiency falls short of meeting needs into Q3 2027
Breaks if: Leadership instability or failure to execute key milestones
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on advancing pivotal clinical trials that could drive future growth.
The market appears to have priced in a significant expectations gap, indicating that investors may be anticipating better performance than what has been delivered so far. The valuation is considered expensive compared to peers, which suggests that the market is not fully accounting for the company's current fragility.
Fundamentals are likely to remain mixed in the near term, with ongoing clinical trials for key products and a focus on maintaining cash sufficiency. The company has shown some recent improvement in financial performance, but risks remain due to its loss-making status and elevated near-term risks.
The thesis hinges on the outcomes of pivotal clinical trials and the ability to maintain cash sufficiency. Additionally, broader sector performance, particularly from leading companies in healthcare, will be crucial in shaping LYEL's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. This miss raises concerns about the company's ability to stabilize and grow revenue beyond FY26.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue decline worsens beyond -60% in FY27
Over the next 1 to 3 years, LYEL's prospects will depend on clinical advancements and sector momentum. Not investment advice.